Table D2. Study characteristics, part 1

| Author, Year  Trial Name | N Eligible | N Randomized | N Completers | N Analyzed | Study Design |
| --- | --- | --- | --- | --- | --- |
| Bender et al., 20101  NA | NR | Overall N: 50  G1: 25  G2: 25 | NR | Overall N: 50  G1: 25  G2: 25 | RCT: parallel, not clustered |
| Berg et al., 19972  NA | Overall N: 87  G1: NR  G2: NR | Overall N: 55  G1: 31  G2: 24 | Overall N: 54  G1: NR  G2: NR | Overall N: 55  G1: 31  G2: 24 | Non-clustered RTC with block randomization by asthma severity |
| Berger et al., 20053 NA | Overall N: NR G1:  G2: | Overall N: 435  G1: 212 G2: 212  (the article does not account for the discrepancy in these numbers) | Overall N: 367 G1: 172 G2: 195 | Overall N: 367 G1: 172 G2: 195 | RCT: parallel, not clustered |
| Bogner et al., 20084  NA | Overall N: 109 prescreened as potentially eligible - 73 provided consent for screening  G1: NR  G2: NR | Overall N: 64  G1: 32  G2: 32 | Overall N: 64  G1: 32  G2: 32 | Overall N: 64  G1: 32  G2: 32 | RCT: parallel, not clustered |
| Bogner et al., 20105 NA | Overall N: 58 G1: 29 G2: 29 | Overall N: 58 G1: 29 G2: 29 | Overall N: 58 G1: 29 G2: 29 | Overall N: 58 G1: 29 G2: 29 | RCT: parallel, not clustered |
| Bosworth et al., 20056 V-STITCH | Overall N: 816 G1: NR G2: NR | Overall N: 588 G1: 294 G2: 294 | Overall N: NR G1: NR G2: NR | Overall N: NR G1: NR G2: NR | RCT: parallel, not clustered |
| Bosworth et al., 20087 TCYB  Bosworth et al., 20078 TCYB Methods paper | Overall N: NR, unclear from text G1: NR G2: NR | Overall N: 636 G1: 319 G2: 317 | Overall N: NR G1: NR G2: NR | Overall N: NR G1: NR G2: NR | RCT: parallel, not clustered |
| Capoccia et al., 20049 NA | Overall N: 89 G1:  G2: | Overall N: 74 G1: 41 G2: 33 | Overall N: 69 G1: 37 G2: 30 | Overall N: 74 G1: 41 G2: 33 | RCT: parallel, not clustered |
| Carter et al., 200910  NA | Overall N: 1242  G1: 568  G2: 674 | Overall N: 402  G1: 192  G2: 210 | Overall N: 332  G1: 158  G2: 174 | Overall N: 402  G1: 192  G2: 210 | RCT: cluster-randomized |
| Chernew et al., 200811 NA | Number of members in health plan Overall N (2004):  G1: 35,807 G2: 74,345 Overall N (2005):  G1: 37,867 G2: 70,259 | NA | NR | For diabetes medications:  2004 (Pre): G1: 919 to 1,245 G2: 3,596 to 4,185  2005 (Post): G1:1,056 to 1,306 G2: 3,535 to 4,072  Unit of observation in analyses was patient-quarter, yielding eight observations per patient | Before-after study |
| Choudhry et al., 201012 NA | Overall N: 52,631 G1: 2051 G2: 779 G3: 38,174 G4: 11,627 | Overall N: NA G1: NA G2: NA | Overall N: 52,631 G1: 2051 G2: 779 G3: 38,174 G4: 11,627 | Overall N: 52,631 G1: 2051 G2: 779 G3: 38,174 G4: 11,627 | Other |
| Choudhry et al., 201113 MI FREEE | Overall N: 6768  G1:  G2: | Overall N: 5855  G1: 2845  G2: 3010 | Overall N: 5571  G1: 2712  G2: 2859 | Overall N: 5571  G1: 2712  G2: 2859 | RCT: cluster-randomized |
| Friedman et al., 199614 NA | Overall N: 964 G1: NR G2: NR | Overall N: 299 G1: NR G2: NR | Overall N: 267 G1: 133 G2: 134 | Overall N: 267 G1: 133 G2: 134 | RCT: parallel, not clustered |
| Fulmer et al., 199915 NA | Overall N: 600 G1:  G2: | Overall N: 60 G1: NR G2: NR G3: NR | Overall N: 50 G1: 17 G2: 15 G3: 18 | Overall N: 50 G1: 17 G2: 15 G3: 18 | RCT: parallel, not clustered |
| Grant et al., 200316  NA | Overall N: 462  G1: 118  G2: 114 G3: 230 | Overall N: 462  G1: 118  G2: 114 G3: 230 | Overall N: 120  G1: 62  G2: 58 | Overall N: 120  G1: 62  G2: 58 | RCT: parallel, not clustered |
| Guthrie et al., 200117 First Myocardial Infarction (MI) Risk Reduction Program | Overall N: NR G1: NR G2: NR | Overall N: 13,100 G1: 10,335 G2: 2,765 | Overall N: 4548 G1: 3635 G2: 913 | Overall N: 4548 G1: 3635 G2: 913 | RCT: parallel, not clustered |
| Hoffman et al., 200318 NA | NR | Overall :  Patients: 9564 Providers: 7021 G1:  Patients: 4899  Providers: 3474 G2:  Patients: 4665 Providers: 3547 | Overall N:  G1:  G2: | Overall N:  G1:  G2: | RCT: cluster-randomized |
| Hunt et al., 200819  NA | Overall N: 2,901 G1: NR G2: NR | Overall N: 463 G1: 230 G2: 233 | Overall N: 272 G1: 142 G2: 130 | Overall N: 272 G1: 142 G2: 130 | RCT: parallel, not clustered |
| Janson et al., 200320 NA | Overall N: NR G1: NR G2: NR | Overall N: 68 G1: NR G2: NR | Overall N: 62 G1: NR G2: NR | Overall N: 65 G1: 33 G2: 32 | RCT: parallel, not clustered |
| Janson et al., 200921 NA | Overall N: 95 G1: NA G2: NA | Overall N: 84 G1: 45 G2: 39 | NR | Overall N:  G1: 45 G2: 39 | RCT: parallel, not clustered |
| Johnson et al., 200623 NR | Overall N: 1227 G1: NR G2: NR | Overall N: NR G1: NR G2: NR | Overall N: NR G1: NR G2: NR | Overall N: 1017 G1: 500 G2: 517 | RCT: parallel, not clustered |
| Johnson et al., 200622 NR | Overall N: 1038 G1: NR G2: NR | Overall N: 404 G1: 202 G2: 202 | Overall N: 262 G1: 114 G2: 148 | Overall N: 404 G1: 202 G2: 202 | RCT: parallel, not clustered |
| Katon et al., 199524  NA | Overall N: 242  G1:  G2: | Overall N: 217  Major depression group N: 91  G1: 49  G2: 42  Minor depression group N: 126  G1: 59  G2: 67 | Overall N: 177  G1: NR  G2: NR | Overall N: 177  G1: NR  G2: NR | RCT: cluster-randomized |
| Katon et al., 199625 NA | Overall N: 183 | Overall N: 153 G1: 77 G2: 76 Major depression: 65 Minor depression: 88 | Overall N: 113 G1: 60 G2: 53 | N analyzed NR, but stated to include "all intervention patients" for adherence outcomes, unclear for other outcomes | RCT: cluster-randomized |
| Katon et al., 200128  NA  Ludman et al., 200329 NA  Van Korff et al., 200330 NA | Overall N: 480 | Overall N: 386 G1: 194 G2: 192 | Overall N: 315 G1: 170 G2: 145 | Overall N: 315 G1: 170 G2: 145 | RCT: parallel, not clustered |
| Katon et al., 199926  NA  Katon et al., 200227  NA | Overall N: 341 | Overall N: 228  G1: 114  G2: 114 | 6 m:Overall N: 167  G1: 87  G2: 80  28 m: Overall N: 171  G1: NR  G2: NR | 6 m:Overall N: 228  G1: 114  G2: 114  28 m:Overall N: 187  G1: 95  G2: 92 | RCT: parallel, not clustered |
| Lee et al., 200631 FAME | Overall N: 208 G1: NR G2: NR | Overall N: 159 G1: 83 G2: 76 | Overall N: 146 G1: 77 G2: 69 | Overall N: 159 G1: 83 G2: 76 | RCT: parallel, not clustered |
| Lin et al., 200632 NA | Overall N: 375 G1: NA G2: NA | Overall N: 329 G1: 164 G2: 165 | Overall N: NR | Overall N: 329 G1: 164 G2: 165 | RCT: parallel, not clustered |
| Maciejewski et al., 20103315257  NA | Overall N: NR G1: NR G2: NR | Enrollees Overall N: 1385391 G1: 747300 G2: 638091 All employers Overall N: 32259 G1: 32083 G2: 176 Underwritten employers Overall N: 32032 G1: 32032 G2: 0 Self-insured employers Overall N: 227 G1: 51 G2: 176 | Overall N: NR G1: NR G2: NR | Enrollees **Overall N**: 1385391 G1: 747300 G2: 638091 **Diuretics** Overall N: NR G1: 15605 G2: 9137 **ACE Inhibitors** Overall N: NR G1: 14250 G2: 7668 **Statins** Overall N: NR G1: 18346 G2: 10162 **Beta Blockers** Overall N: NR G1: 11137 G2: 6343 **Calcium Channel Blockers** Overall N: NR G1: 7191 G2: 4099 **Metformin** Overall N: NR G1: 5077 G2: 2826 **ARBs**  Overall N: NR G1: 7445 G2: 4514 **Cholesterol Absorption Inhibitors** Overall N: NR G1: 4019 G2: 2291 | Retrospective quasi-experimental |
| Mann et al., 201034 The Statin Choice | NR | Overall N: 150 G1: 80  G2: 70 | NR | NR | RCT: parallel, not clustered |
| Montori et al., 201135  NA | Overall N: 102 G1: NA G2: NA | Overall N: 100 G1: 52 G2: 48 | Overall N: 93 G1: 47 G2: 46 | Overall N: 100 G1: 52 G2: 48 | RCT: parallel, not clustered |
| Murray et al., 200736  NA | Overall N: 1512 G1: NR  G2: NR | Overall N: 314  G1: 122  G2: 192 | Overall N: 270  G1: 106  G2: 164 | Overall N: 314  G1: 122  G2: 192 | Randomized clinical trial |
| Nietert et al., 200937 NA | Overall N: 3048 G1: NR G2: NR G3: NR | Overall N: 3048 G1: 1018 G2: 1016 G3: 1014 | Overall N: 2590 G1: 869 G2: 863 G3: 858 | Overall N: 3048 G1: 1018 G2: 1016 G3: 1014 | RCT: parallel, not clustered |
| Okeke et al., 200938 NA | Overall N: 66 G1:  G2: | Overall N: 66 G1: 35 G2: 31 | Overall N: NR G1: NR G2: NR | Overall N: 66 G1: 35 G2: 31  \*4 excluded from multivariate analysis (1 from G1 and 2 from G2) due to missing value in education (N=2), Asian race (N=1), and use of travoprost without using dosing aid (N=1) | RCT: parallel, not clustered |
| Pearce et al., 200839 Cardiovascular Risk Education and Social Support (CaRESS) Trial | Overall N: 233 G1: NR G2: NR G3: NR | Overall N: 199 G1: 50 G2: 58 G3: 91 | Overall N: 153 G1 + G2: 81 G3: 72 | Overall N: 199 G1: 50 G2: 58 G3: 91 | RCT: cluster-randomized |
| Powell et al., 199540 NA | Overall N: NR G1: NR G2: NR | Overall N: 4246 G1: 1993 G2: 2253 | Overall N: 4246 G1: 1993 G2: 2253 | Overall N: 4246 G1: 1993 G2: 2253 | RCT: cluster-randomized |
| Powers et al., 201168 | Overall N: 278 G1: NR G2: NR | Overall N: 89 G1: 44 G2: 45 | Overall N: 89 G1: 44 G2: 45 | Overall N: 89 G1: 44 G2: 45 | RCT: parallel, not clustered |
| Pyne et al., 201141 HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | Overall N: 448 G1: NA G2: NA | Overall N: 276 G1: 138 G2: 138 | Overall N: 225 G1: 105 G2: 110 | Overall N: 249 G1: 123 G2: 126 | RCT: parallel, not clustered |
| Rich et al., 199642 NA | Overall N: NR G1: NR G2: NR | Overall N: 156 G1:80  G2: 76 | Overall N: NR G1: NR G2: NR | Overall N: 156 G1:80  G2: 76 | RCT: parallel, not clustered |
| Rickles et al., 200543  NA | Overall N: 63  G1:  G2: | Overall N: 63  G1: 31  G2: 32 | Overall N: G1: 28  G2:32 | Overall N:  G1: 28  G2: 32 | RCT: parallel, not clustered |
| Ross et al., 200444 NR | Overall N: NR G1: NR G2: NR | Overall N: 107 G1: 54 G2: 53 | Overall N: 81  G1: 38 G2: 43 | Overall N: NR G1: NR G2: NR | RCT: parallel, not clustered |
| Rudd et al., 200445 NA | Overall N: 837 G1: NR G2: NR | Overall N: 150 G1: 74 G2: 76 | Overall N: 137 G1: 69 G2: 68 | Overall N: 150 G1: 74 G2: 76 | RCT: parallel, not clustered |
| Rudd et al., 200946 NA | Overall N: 408 G1:  G2: | Overall N: 127 G1: 64 (51 Individualized Care, 13 Plain English) G2: 63 | Overall N: 105 G1: 48 G2: 57 | Overall N: 127 G1: 64 G2: 63 | Other |
| Schaffer et al., 200447 NA | Overall N: NR G1: NR G2: NR G3: NR G4:NR | Overall N: 46 G1: NR G2: NR G3: NR G4:NR | Overall N: 44 G1: NR G2: NR | Overall N: 46  G1: 11 G2: 10 G3:12 G4:13 | RCT: parallel, not clustered |
| Schectman et al., 199448 NA | Overall N: NR Niacin G1: 102 BAS G2: 62 | Niacin Overall N: 102 G1: 52 G2: 50  BAS Overall N: 62 G1: 31 G2: 31 | Niacin Overall N: 102 G1: 52 G2: 50  BAS Overall N: 60 G1: 29 G2: 31 | Niacin Overall N: 80 G1: 40 G2: 40  BAS Overall N: 40 G1: 18 G2: 22 | RCT: parallel, not clustered |
| Schneider et al., 200849 NA | Overall N: 112 G1: NR G2: NR | Overall N: 93 G1: NR G2: NR | Overall N: 85 G1: 47 G2: 38 | Overall N: 85 G1: 47 G2: 38 | RCT: parallel, not clustered |
| Schnipper et al., 200650 NA | Overall N: 291 G1:  G2: | Overall N: 178 G1: 92 G2: 84 | Overall N: 152 G1: 79 G2: 73 | Overall N: 152 G1: 79 G2: 73 | RCT: parallel, not clustered |
| Simon et al., 200651  NA | Overall N: 217  G1: NR  G2: NR | Overall N: 207  G1: NR  G2: NR | Overall N: NR  G1: NR  G2: NR | Overall N: G1: symptom analysis:  94  utilization analysis: 98  G2: symptom analysis: 94  utilization analysis: 97 | RCT: parallel, not clustered |
| Sledge et al., 200652 NA | Overall N: 238 G1:  G2: | Overall N: 96 G1: 47 G2: 49 | Overall N: 75 G1: 36 G2: 39 | Overall N: 75 G1: 36 G2: 39 | RCT: parallel, not clustered |
| Smith et al., 200853 NR | Overall N: NR G1: NR G2: NR | Overall N: 907 G1: 458 G2: 449 | Overall N: 836 G1: 426 G2: 410 | Overall N: 836 G1: 426 G2: 410 | RCT: cluster-randomized |
| Solomon et al., 199854 NA  Gourley et al., 199855 NA | Overall N: NR G1: NR G2: NR | Overall N: NR G1: NR G2: NR | Overall N:  HTN:133 COPD:98 G1 (HTN): 63 G2 (HTN): 70 G1 (COPD): 43 G2 (COPD): 55 | Overall N:  HTN: 133 COPD: 98 G1 (HTN): 63 G2 (HTN):70 G1 (COPD): 43 G2 (COPD): 55 | RCT: parallel, not clustered |
| Stacy et al., 200956 NA | Overall N: 5174 G1:  G2: | Overall N: 578 G1: 298 G2: 280 | Overall N: 497 G1: 253 G2: 244 | Overall N: 497 G1: 253 G2: 244 | RCT: parallel, not clustered |
| Taylor et al., 200357 NA | Overall N: NR G1:  G2: | Overall N: 81 G1: NR G2: NR | Overall N: 69 G1: 33 G2: 36 | Overall N: 69 G1: 33 G2: 36 | RCT: parallel, not clustered |
| Vivian et al., 200258 NA | Overall N: 56 G1: NA G2: NA | Overall N: 56  G1: 27 G2: 29 | Overall N: 53 G1: 26 G2: 27 | Overall N: 53 G1: 26 G2: 27 | RCT: parallel, not clustered |
| Waalen et al., 200959 NA | Overall N: 442 G1:  G2: | Overall N: 235 G1: 125 G2: 110 | Overall N: 211 G1: 109 G2: 102 | Overall N: 211 G1: 109 G2: 102 | RCT: parallel, not clustered |
| Wakefield et al., 201160 | Overall N: 304 G1: NR G2: NR G3:NR | Overall N: 302 G1: 93 G2: 102 G3: 107 | Overall N: 246 G1: 73 G2: 79 G3: 94 | Overall N: NR G1: NR G2: NR G3:NR | RCT: parallel, not clustered |
| Weinberger et al., 200261  NA | Overall N: 14195  G1: NR  G2: NR  G3:N  Religible for initial criteria | Overall N: 1113  G1: 446  G2: 363  G3: 303 | Overall N: 898  G1: 356  G2: 296  G3: 246 | Overall N: 898  G1: 356  G2: 296  G3: 246 | RCT: cluster-randomized |
| Weymiller et al., 200762 Statin Choice Randomized Trial  Jones et al., 200963 Statin Choice Randomized Trial | Overall N: 124 G1: NA G2: NA | Overall N: 98 G1: 52 G2: 46 | Overall N: 97 G1: 51 G2: 46 | Overall N: 97 G1: 51 G2: 46 | RCT: cluster-randomized |
| Williams et al., 201064 NA | Overall N: 207 MDs (34 practices) G1: NA G2: NA | Overall N: 34 practices (207 providers); G1: 17 practices (88 providers; 1335 patients) G2: 17 practices (105 providers; 1363 patients) | Overall N: 34 practices (206 providers) G1: 17 practices (87 providers; 1040 patients);  G2: 17 practices (105 providers; 1034 patients) | Overall N:  G1:  G2: | RCT: cluster-randomized |
| Wilson et al., 201065 Better Outcomes of Asthma Treatment (BOAT) | Overall N: 1070 G1:  G2: | Overall N: 612 G1: 204 G2: 204 G3: 204 | Overall N: 551 G1: 182 G2: 180 G3: 189 | Varies by outcome | RCT: parallel, not clustered |
| Wolever et al., 201066 NA | Overall N: 64 G1: NR G2: NR | Overall N: 56 G1: 30 G2: 26 | Overall N: 47 G1: 25 G2: 22 | Overall N: 49 G1: 27 G2: 22 | RCT: parallel, not clustered |
| Zhang et al., 201067 NA | Overall N: 20,889 G1,G2,G3: Total of 14,965 G4: 5,924 | NA | NA | Overall N: 20,889 G1, G2, G3: Total of 14,965 G4: 5924 | Before-after study |